A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY).

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MOLLY
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Mar 2012 Actual initiation date changed from 1 Nov 2009 to 16 Oct 2009 as reported by European Clinical Trials Database.
    • 12 Jul 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top